Certican derives Successful Result


Certican derives Successful Result

Surely, it was a good news for Novartis that it has been able to have positive result of its phase III clinical study of immune system drug known as Certican. The news was worth getting happy, as it has been found that the Swiss pharmaceutical company was trying to get everything right for last two years.

In addition, it has been said that the project is considered to be the biggest project that has been taken out by the company with regard to liver transplant. It has been found that the drug is quite effective in improving renal function among patients.

The data about the same was revealed at the meeting of American Association for the Study of Liver Diseases (AASLD), which is in its 63rd year. The drug, which has already received approval from European health authorities, is likely to get approval from the US health regulators Food and Drug Administration by the end of 2012.

"These results showed that treatment with Certican with reduced tacrolimus led to a clinically relevant retention of renal function compared to standard tacrolimus, with no compromise in rejection", said John Fung, who is positioned as director at Transplantation Center. It is expected that the drug is able to provide benefit to adults suffering from liver problem.

Latest News

Rupert Murdoch Tweets Tribune Probably Selling Los Angeles Times
Black Friday Shopping “Uninspiring” in Brick and Mortar Stores; Shopping Trends
U.S. Crude Drops Further Due to Surplus Supply
CVC and CPPIB Outbid Others for a Possible Deal to Buy Petco for $4.7 Billion
US Government All Set to Introduce a New Law for Americans “Seriously Delinquent
Reportedly Pfizer Plans to Acquire Allergan in a Deal of $150 Billion or More
In October Most States Experienced a Drop in Unemployment Rate
San Francisco Fed President John Williams sees a “Strong Case” for an Interest
Cincinnati Shoppers have More Choice of Local Black Friday Deals this Year
Sliding Crude Prices Continue Giving the U.S Oil Producers Reasons to Cut Costs
American Airlines Revamps its Much Anticipated Loyalty Reward Program
Report says, Many Retailers Recycling Black Friday Deals